269 related articles for article (PubMed ID: 24053454)
1. The role of ursodeoxycholic acid in non-alcoholic steatohepatitis: a systematic review.
Xiang Z; Chen YP; Ma KF; Ye YF; Zheng L; Yang YD; Li YM; Jin X
BMC Gastroenterol; 2013 Sep; 13():140. PubMed ID: 24053454
[TBL] [Abstract][Full Text] [Related]
2. Treatment of NASH with ursodeoxycholic acid: cons.
Liechti F; Dufour JF
Clin Res Hepatol Gastroenterol; 2012 Sep; 36 Suppl 1():S46-52. PubMed ID: 23141894
[TBL] [Abstract][Full Text] [Related]
3. Treatment of NASH with ursodeoxycholic acid: pro.
Ratziu V
Clin Res Hepatol Gastroenterol; 2012 Sep; 36 Suppl 1():S41-5. PubMed ID: 23141893
[TBL] [Abstract][Full Text] [Related]
4. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial.
Lindor KD; Kowdley KV; Heathcote EJ; Harrison ME; Jorgensen R; Angulo P; Lymp JF; Burgart L; Colin P
Hepatology; 2004 Mar; 39(3):770-8. PubMed ID: 14999696
[TBL] [Abstract][Full Text] [Related]
5. Efficiency of ursodeoxycholic acid for the treatment of nonalcoholic steatohepatitis: A systematic review and meta-analysis.
Lin X; Mai M; He T; Huang H; Zhang P; Xia E; Guo H
Expert Rev Gastroenterol Hepatol; 2022 Jun; 16(6):537-545. PubMed ID: 35617696
[TBL] [Abstract][Full Text] [Related]
6. [UDCA in the treatment of nonalcoholic fatty liver disease].
Grigor'eva IN
Eksp Klin Gastroenterol; 2011; (11):79-85. PubMed ID: 22629725
[TBL] [Abstract][Full Text] [Related]
7. Omega-3 polyunsaturated fatty acid and ursodeoxycholic acid have an additive effect in attenuating diet-induced nonalcoholic steatohepatitis in mice.
Kim JK; Lee KS; Lee DK; Lee SY; Chang HY; Choi J; Lee JI
Exp Mol Med; 2014 Dec; 46(12):e127. PubMed ID: 25523099
[TBL] [Abstract][Full Text] [Related]
8. A randomized controlled trial comparing the effects of Vitamin E, Ursodeoxycholic acid and Pentoxifylline on Egyptian non-alcoholic steatohepatitis patients.
Fouda A; Abdelaziz AE; Hussien M; Ali AA; Abdelkawy KS; Elbarbry F
Eur Rev Med Pharmacol Sci; 2021 Dec; 25(23):7449-7459. PubMed ID: 34919247
[TBL] [Abstract][Full Text] [Related]
9. A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis.
Ratziu V; de Ledinghen V; Oberti F; Mathurin P; Wartelle-Bladou C; Renou C; Sogni P; Maynard M; Larrey D; Serfaty L; Bonnefont-Rousselot D; Bastard JP; Rivière M; Spénard J;
J Hepatol; 2011 May; 54(5):1011-9. PubMed ID: 21145828
[TBL] [Abstract][Full Text] [Related]
10. [UDCA in the treatment of nonalcoholic fatty liver disease].
Grigor'eva IN
Eksp Klin Gastroenterol; 2011; (9):125-31. PubMed ID: 22629789
[TBL] [Abstract][Full Text] [Related]
11. Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis.
Dufour JF; Oneta CM; Gonvers JJ; Bihl F; Cerny A; Cereda JM; Zala JF; Helbling B; Steuerwald M; Zimmermann A;
Clin Gastroenterol Hepatol; 2006 Dec; 4(12):1537-43. PubMed ID: 17162245
[TBL] [Abstract][Full Text] [Related]
12. [Treatment of non-alcoholic steatohepatitis (NASH). A comparative study of ursodeoxycholic acid and alpha-tocopherol. A preliminary report].
Bernal-Reyes R; Escudero RB
Rev Gastroenterol Mex; 2002; 67(2):70-5. PubMed ID: 12214337
[TBL] [Abstract][Full Text] [Related]
13. Effects of ursodeoxycholic acid therapy on carotid intima media thickness, apolipoprotein A1, apolipoprotein B, and apolipoprotein B/A1 ratio in nonalcoholic steatohepatitis.
Ozel Coskun BD; Yucesoy M; Gursoy S; Baskol M; Yurci A; Yagbasan A; Doğan S; Baskol G
Eur J Gastroenterol Hepatol; 2015 Feb; 27(2):142-9. PubMed ID: 25533429
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic options in non-alcoholic steatohepatitis (NASH). Are all agents alike? Results of a preliminary study.
Georgescu EF; Georgescu M
J Gastrointestin Liver Dis; 2007 Mar; 16(1):39-46. PubMed ID: 17410287
[TBL] [Abstract][Full Text] [Related]
15. Effects of ursodeoxycholic acid and/or low-calorie diet on steatohepatitis in rats with obesity and hyperlipidemia.
Fan JG; Zhong L; Tia LY; Xu ZJ; Li MS; Wang GL
World J Gastroenterol; 2005 Apr; 11(15):2346-50. PubMed ID: 15818751
[TBL] [Abstract][Full Text] [Related]
16. UDCA for NASH: end of the story?
Haedrich M; Dufour JF
J Hepatol; 2011 May; 54(5):856-8. PubMed ID: 21145815
[No Abstract] [Full Text] [Related]
17. Ursodeoxycholic acid ameliorates hepatic lipid metabolism in LO2 cells by regulating the AKT/mTOR/SREBP-1 signaling pathway.
Hu J; Hong W; Yao KN; Zhu XH; Chen ZY; Ye L
World J Gastroenterol; 2019 Mar; 25(12):1492-1501. PubMed ID: 30948912
[TBL] [Abstract][Full Text] [Related]
18. [Comparison on the efficacy and safety of biphenyl dimethyl dicarboxylate and ursodeoxycholic acid in patients with abnormal alanine aminotransferase: multicenter, double-blinded, randomized, active-controlled clinical trial].
Lee SH; Cheon GJ; Kim HS; Kim YD; Kim SG; Kim YS; Jeong SW; Jang JY; Kim BS
Korean J Gastroenterol; 2014 Jul; 64(1):31-9. PubMed ID: 25073669
[TBL] [Abstract][Full Text] [Related]
19. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study.
Laurin J; Lindor KD; Crippin JS; Gossard A; Gores GJ; Ludwig J; Rakela J; McGill DB
Hepatology; 1996 Jun; 23(6):1464-7. PubMed ID: 8675165
[TBL] [Abstract][Full Text] [Related]
20. Bile acids for non-alcoholic fatty liver disease and/or steatohepatitis.
Orlando R; Azzalini L; Orando S; Lirussi F
Cochrane Database Syst Rev; 2007 Jan; (1):CD005160. PubMed ID: 17253541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
